10C
Delhi
Monday, January 25, 2021

SII, Bharat Biotech asked to submit more data for vaccine’s emergency approval

- Advertisement -

‘Covaxin likely to be available for public use by Feb’New Delhi, Dec 9 (IANS) The Central Drugs Standard Control Organisation’s Subject Expert Committee on Wednesday asked the Serum Institute of India and Bharat Biotech to submit more data and information to get emergency use authorisation (EUA) for their Covid-19 vaccine candidates.

According to the minutes of the meeting, the committee recommended the Serum Institute of India to submit the updated safety data of the Phase 2/3 clinical trials, immunogenicity data from the clinical trial in UK and India, and outcome of the assessment of UK-MHRA for grant of EUA.

During the meeting, the SII presented their proposal for grant of EUA of COVISHIELD, along with the interim safety data from Phase 3 clinical trial and interim safety and efficacy results of Phase 2/3 and Phase 3 clinical trials carried out in UK, other countries and India, before the committee.

READ ALSO:  40 cr Indian workers may sink into poverty due to COVID-19: ILO

In the case of Bharat Biotech, the firm presented their proposal for grant of EUA, along with the interim safety and immunogenicity data of Phase 1 and 2 clinical trial carried out in the country before the committee.

“After detailed deliberation, the committee recommended that the firm should present the safety and efficacy data from the ongoing Phase 3 clinical trial in the country for further consideration,” the minutes of the meeting showed.

America’s Pfizer was the first to apply on December 4, followed by Pune-based SII and Hyderabad-based Bharat Biotech who applied on December 6 and 7, respectively. Pfizer has, however, requested more time to make presentation before the committee.

Emergency Use Authorisation is a mechanism to facilitate the availability and use of medical countermeasures, including vaccines, during public health emergencies. Such an approval was given to Covid-19 drugs – remdesivir and favipiravir in June and itolizumab in July.

READ ALSO:  Indians searched for Covid-19 vaccine the most in May: Google

On Tuesday, the Union Health Ministry informed that as many as eight Covid-19 vaccine candidates are under different stages of clinical trials which could be ready for authorization in near future.

READ ALSO:  New method to help detect at-risk areas for Covid-19 spread

Theus includes Astrazeneca and Oxford University developed and Serum Institute of India manufactured Covishield, Covaxin by Bharat Biotech, ZyCoV-D by Zydus Cadila, Russian vaccine candidate Sputnik-V, NVX-CoV2373 by SII, HGCO19 by Geneva, and two unlabeled vaccines – the Recombinant Protein Antigen based vaccine by Biological E Ltd, and Inactivated rabies vector platform by Bharat Biotech.

Source: IANS

India Updates
India Updates is an independent news & Information website. Follow us for regular updates on News and Information.

Follow Us On

Related News

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Trending Topics In India

Covid 19 India Updates

Trending News In India

Trending Showbiz

Trending Sports

Latest Trending News In India

Danish film ‘Into the Darkness’ wins Golden Peacock award at IFFI

Panaji, Jan 24 (IANS) Danish film "Into the Darkness" won the prestigious Golden Peacock award for the "Best Film" at the 51st International Film...

Logistics players expect working capital package in Budget

New Delhi, Jan 24 (IANS): The logistics industry which has been impacted by the pandemic expects the upcoming Union Budget to announce a working capital...

CAIT seeks action against Amazon, Zomato for ‘daylight robbery’

New Delhi, Jan 24 (IANS) The Confederation of All India Traders (CAIT) in a communication sent to Union Commerce Minister Piyush Goyal demanded immediate...

Textile body seeks customs duty hike on man-made yarns in Budget

New Delhi, Jan 24 (IANS) The Northern India Textile Mills' Association (NITMA) has urged the government to raise customs duty on man-made yarns to...